恒瑞医药：多款药品纳入2025年国家医保目录

Core Viewpoint - Heng Rui Medicine announced that several products will be included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025), effective from January 1, 2026 [1] Group 1: Product Inclusion - Ten products, including injection of Rui Kang Qu Tuo Zhuan Tan, are newly included in the drug list [1] - Three products, including injection of Ka Li Li Zhuan Tan, have new indications added to the list [1] - Five products, including Maleate Pyrolitin Tablets, have successfully renewed their contracts [1] Group 2: Adjustments and Sales Impact - Two products, including Methanesulfonic Acid Apatinib Tablets, have new indications and are adjusted to regular directory management [1] - The total sales revenue of the aforementioned drugs is approximately 8.66 billion yuan for the year 2024 and about 7.55 billion yuan for the first three quarters of 2025 [1] - The impact on the company's performance from these changes is currently difficult to estimate [1]